Endocrinologia
Cem anos de insulinoterapia.
14 Set, 2021 | 14:17hOne hundred years of insulin therapy – Nature Reviews Endocrinology
Comentário no Twitter
To mark the centenary of the discovery of #insulin, Chantal Mathieu, Pieter-Jan Martens & Roman Vangoitsenhoven look back on the past one hundred years of insulin therapy and discuss future directions https://t.co/kYxVIpzXda #diabetes pic.twitter.com/z9uendON7w
— Nature Reviews Endocrinology (@NatureRevEndo) September 11, 2021
Diferentes riscos e benefícios levam a custos similares após gastroplastia vertical e bypass gástrico em Y de Roux.
12 Set, 2021 | 22:01hEstudo original: Comparison of 4-Year Health Care Expenditures Associated With Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy – JAMA Network Open
Comentário no Twitter
Cohort study found that 4-year healthcare expenditures associated with Roux-en-Y gastric bypass (RYGB) surgery and sleeve gastrectomy (SG) did not differ in Ontario, Canada. https://t.co/pegVdcwgJG
— JAMA Network Open (@JAMANetworkOpen) September 9, 2021
Revisão sistemática | Avaliação dos padrões dietéticos e mortalidade por todas as causas.
6 Set, 2021 | 16:24hEvaluation of Dietary Patterns and All-Cause Mortality: A Systematic Review – JAMA Network Open
Comentário no Twitter (fio – clique para saber mais)
Great to see work focused on diet patterns (rather than single nutrient/foods)
Nutrient-dense diet patterns, regardless of pattern label/name (Med Diet, DASH, HEI, "plant-based"), were associated with significantly lower risk of death
Commonalities?👇https://t.co/yQxo4lNJNQ
— Stephan van Vliet (@vanvlietphd) September 1, 2021
Estudo mostra que as crianças ganharam peso durante a pandemia.
2 Set, 2021 | 11:22hNews release: Young children gained weight during the pandemic – Kaiser Permanente
Estudo original: Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic – JAMA
Comentário no Twitter
#KPResearch showed significant weight gain occurred during COVID-19 pandemic among youth in Southern California, especially among youngest kids.
Research: @KPSCalResearch & @UMchear
In @JAMANetwork
Authors incl @CKoebnickPhD @RohmDeborah @MargoSidell https://t.co/IqiUxo75bW pic.twitter.com/8XA7G6J3Bu— Kaiser Permanente Research (@KPSCalResearch) August 27, 2021
#ESCCongress | Diretrizes 2021 da ESC sobre prevenção de doença cardiovascular na prática clínica.
2 Set, 2021 | 11:15hComunicado de imprensa: How can I avoid heart disease or stroke? – European Society of Cardiology
Pontos-chave: 2021 ESC Guidelines on CVD Prevention in Clinical Practice – American College of Cardiology
Comentário no Twitter
NEW: #ESCGuidelines on cardiovascular disease prevention in clinical practice https://t.co/9a71ZGBCCF#ESCCongress #cardiotwitter #EAPC_ESC #medtwitter pic.twitter.com/ZPCJPksM91
— European Society of Cardiology (@escardio) August 30, 2021
#ESCCongress – M-A | Polipílulas com e sem aspirina reduziram sobremaneira a ocorrência de doença cardiovascular, infarto do miocárdio, AVC, revascularização e morte por causa cardiovascular na prevenção primária de doença cardiovascular.
2 Set, 2021 | 11:06hFixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis – The Lancet (link para o resumo – $ para o texto completo)
Comentário: Combo therapy cuts risk of heart attacks and strokes in half – McMaster University
Conteúdos relacionados:
Opinion: A new important study supports wider use of the polypill
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era
Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population
Perspective: The Polypill and the Long Journey to Major Impact
Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
Consenso | Definição e intepretação da remissão no diabetes tipo 2 – HbA1c < 6,5%, medida pelo menos 3 meses depois da cessação da farmacoterapia para redução de glicose, foi sugerido como critério diagnóstico.
2 Set, 2021 | 11:04hComunicado de imprensa: International Experts Outline Diabetes Remission Diagnosis Criteria – Endocrine Society
#ESCCongress | Estudo randomizado: inibição de SGLT2 reduziu o risco combinado de morte cardiovascular ou hospitalização em pacientes com insuficiência cardíaca e fração de ejeção preservada, independentemente da presença ou ausência de diabetes.
30 Ago, 2021 | 13:21hEmpagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine
Comunicado de imprensa: Trial reports first successful results for heart failure with preserved ejection fraction – European Society of Cardiology
Comentário no Twitter
#FIGARO-DKD #ESCCongress
🔺in patients w T2D & microalbuminuria & stage 1-4 CKD, finerenone vs placebo led to 13% relative ⬇️in CV events (mostly due to 29%⬇️in HF hospitalizations)
🔺~2/3 pts +microalbuminuria w normal GFR:🔑 is to✔️in T2D#ESCCongress https://t.co/8oT5s8KjT0 pic.twitter.com/fQbmUzPasD— Ritu Thamman MD (@iamritu) August 28, 2021
#ESCCongress | Estudo randomizado: finerenona reduziu os eventos cardiovasculares em pacientes com doença renal e diabetes tipo 2 (12,4% vs. 14,2% durante um seguimento médio de 3,4 anos), mas o risco de hiperpotassemia foi aumentado (10,8% vs. 5,3%).
30 Ago, 2021 | 13:16hComunicado de imprensa: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology
Comentários:
Conteúdo relacionado: [Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes
Comentário no Twitter
FIGARO-DKD: Among patients with stage 1 to 4 CKD and T2 diabetes, finerenone improved CV outcomes as compared with placebo. #ESCCongress https://t.co/mcfmvftBvy pic.twitter.com/qizit80NBa
— NEJM (@NEJM) August 28, 2021